AMCIPATRICIN DIASCORBATE

Details

Stereochemistry	EPIMERIC
Molecular Formula	C67H103N5O19.2C6H8O6
Molecular Weight	1634.8051
Optical Activity	UNSPECIFIED
Defined Stereocenters	22 / 23
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO.[H][C@@]2(OC(=O)C(O)=C2O)[C@@H](O)CO.[H][C@]34C[C@@H](O[C@]5([H])O[C@H](C)[C@@H](O)[C@H](NC(=O)CN(C)C)[C@@H]5O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@]([H])(OC(=O)C[C@H](O)CC(=O)C[C@H](O)C[C@H](O)C[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]3C(=O)NCCN(C)C)O4)[C@@H](C)CCC(O)CC(=O)C6=CC=C(NC)C=C6

InChI

InChIKey=VUJFLULIGNDMNL-VJVWVGQESA-N

InChI=1S/C67H103N5O19.2C6H8O6/c1-42-21-19-17-15-13-11-9-10-12-14-16-18-20-22-54(89-66-63(85)61(62(84)44(3)88-66)70-58(82)41-72(7)8)38-57-60(65(86)69-29-30-71(5)6)56(81)40-67(87,91-57)39-53(79)35-51(77)33-49(75)31-48(74)32-50(76)34-52(78)37-59(83)90-64(42)43(2)23-28-47(73)36-55(80)45-24-26-46(68-4)27-25-45;2*7-1-2(8)5-3(9)4(10)6(11)12-5/h9-22,24-27,42-44,47-49,51-54,56-57,60-64,66,68,73-75,77-79,81,84-85,87H,23,28-41H2,1-8H3,(H,69,86)(H,70,82);2*2,5,7-10H,1H2/b10-9+,13-11+,14-12+,17-15+,18-16+,21-19+,22-20+;;/t42-,43-,44+,47?,48+,49-,51-,52+,53-,54-,56-,57-,60+,61-,62+,63-,64-,66-,67+;2*2-,5+/m000/s1

HIDE SMILES / InChI

Molecular Formula	C6H8O6
Molecular Weight	176.1241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C67H103N5O19
Molecular Weight	1282.5568
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	18 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16121692 | https://www.ncbi.nlm.nih.gov/pubmed/12868560 | https://www.ncbi.nlm.nih.gov/pubmed/11786653

SPK-843 is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.

Originator

Approval Year

PubMed

Title	Date	PubMed
SPK-843 (Aparts/Kaken).	2005 Aug	16121692

Patents

Sample Use Guides

In Vivo Use Guide

0.5 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:13:44 GMT 2023` Edited by `admin` on `Fri Dec 15 15:13:44 GMT 2023`
Record UNII	7T591796IJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMCIPATRICIN DIASCORBATE

Common Name

English

CANDICIDIN D, 18-DECARBOXY-40-DEMETHYL-3,7-DIDEOXO-N3'- ((DIMETHYLAMINO)ACETYL)-18-(((2-(DIMETHYLAMINO)ETHYL)AMINO)CARBONYL)- 3,7-DIHYDROXY-N47-METHYL-5-OXO-, CYCLIC 15,19-HEMIACETAL, COMPD. WITH L-ASCORBIC ACID (1:2)

Common Name

English

SPA-S-843

Code

English

SPK-843

Code

English

SPA-843

Code

English

Code System Code Type Description

DRUG BANK

DB12333